• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-alkylpiperazines

Cis-4-(4-Methylpiperazin-1-yl)cyclohexan-1-amine Trihydrochloride and Its Significance in Modern Pharmaceutical Research

The compound with the CAS number 723341-87-5 represents a fascinating molecule in the realm of pharmaceutical chemistry, specifically categorized as Cis-4-(4-Methylpiperazin-1-yl)cyclohexan-1-amine Trihydrochloride. This trihydrochloride salt form of the compound has garnered significant attention due to its unique structural and pharmacological properties, making it a valuable candidate for various research applications.

In the context of modern drug discovery, the structural motif of this compound is particularly noteworthy. The presence of a piperazine ring linked to a cyclohexane amine moiety introduces a high degree of conformational flexibility, which is often exploited in medicinal chemistry to modulate binding interactions with biological targets. The Cis configuration further adds to this complexity, influencing both the electronic and steric properties of the molecule.

Recent advancements in computational chemistry have enabled researchers to delve deeper into the structural characteristics of such compounds. Molecular modeling studies suggest that Cis-4-(4-Methylpiperazin-1-yl)cyclohexan-1-amine Trihydrochloride exhibits favorable binding affinities with certain enzymes and receptors, making it a promising scaffold for developing novel therapeutic agents. The trihydrochloride form enhances solubility, which is a critical factor in drug formulation and bioavailability.

The pharmacological profile of this compound has been extensively studied in preclinical models. Initial investigations have highlighted its potential as an intermediate in the synthesis of more complex molecules with therapeutic implications. Specifically, its ability to interact with multiple targets suggests that it could be a versatile building block for drugs targeting neurological and cardiovascular disorders.

One of the most intriguing aspects of Cis-4-(4-Methylpiperazin-1-yl)cyclohexan-1-amine Trihydrochloride is its analogical relationship to other well-known pharmaceuticals. The piperazine moiety, in particular, is a common pharmacophore found in many drugs used to treat conditions such as depression, anxiety, and hypertension. By understanding the structural determinants that contribute to its activity, researchers can design analogs with improved pharmacokinetic properties and reduced side effects.

The synthesis of this compound has also been optimized to ensure scalability and cost-effectiveness. Advanced synthetic methodologies have been employed to achieve high yields and purity levels, which are essential for pharmaceutical applications. These methodologies often involve multi-step reactions that require careful control of reaction conditions to prevent unwanted byproducts.

In terms of biological activity, preliminary data indicate that Cis-4-(4-Methylpiperazin-1-yl)cyclohexan-1-amine Trihydrochloride may exhibit inhibitory effects on certain enzymes implicated in inflammatory pathways. This finding aligns with the growing interest in developing drugs that modulate inflammation without causing significant side effects. Such compounds could have broad therapeutic applications, including in autoimmune diseases and chronic inflammatory conditions.

The role of computational tools in analyzing the pharmacological properties of this compound cannot be overstated. High-throughput virtual screening (HTVS) has been utilized to identify potential binding sites on biological targets, providing insights into how the molecule interacts at a molecular level. These computational studies are often complemented by experimental validation using techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy.

Future directions in research involving Cis-4-(4-Methylpiperazin-1-yl)cyclohexan-1-amine Trihydrochloride may include exploring its potential as a prodrug or a lead compound for further derivatization. The flexibility offered by its structure allows for modifications that could enhance its bioavailability or target specificity. Additionally, investigating its behavior in vivo will provide crucial data on its metabolic stability and potential toxicity profiles.

The significance of this compound extends beyond its immediate therapeutic applications. It serves as a valuable tool for understanding fundamental principles in drug design and development. By studying molecules like Cis-4-(4-Methylpiperazin-1-yl)cyclohexan-1-amine Trihydrochloride, researchers can gain insights into how structural features influence biological activity, paving the way for more rational and efficient drug discovery processes.

In conclusion, Cis-4-(4-Methylpiperazin-1-yl)cyclohexan-1-amine Trihydrochloride (CAS no 723341-87-5) represents a compelling subject of study in pharmaceutical chemistry. Its unique structural features, coupled with promising preclinical data, make it a candidate for further exploration in drug development. As research continues to uncover new applications and mechanisms of action, this compound is poised to play an important role in addressing unmet medical needs.

• 865144-53-2(Piperazinium, 4-cyclohexyl-1,1-dimethyl-, hydroxide (1:1))
• 182141-99-7((R)-1-CYCLOHEXYL-3-METHYL-PIPERAZINE)
• 16018-31-8(Piperazine,1,4-dicyclohexyl-, hydrochloride (1:2))
• 5467-34-5((4aS,8aS)-1,4-dibutyl-2,3,4a,5,6,7,8,8a-octahydroquinoxaline)
• 1187930-87-5((S)-1-Cyclohexyl-3-methylpiperazine)
• 5467-39-0(Quinoxaline,decahydro-1-methyl-, cis-)
• 6327-21-5(2,4,6-Pyrimidinetriamine,N4-(3,4-dimethylphenyl)-5-ethyl-)
• 6335-62-2(Quinoxaline,decahydro-1-methyl-, (4aR,8aR)-rel-)
• 17766-28-8(1-Cyclohexylpiperazine)
• 6640-42-2(Quinoxalinium,1,1,4,4-tetrabutyldecahydro-, dichloride, trans- (9CI))